Dendrimer-Coated Gold Nanoparticles for Efficient Folate-Targeted mRNA Delivery In Vitro

Mbatha, Londiwe Simphiwe; Maiyo, Fiona; Daniels, Aliscia; Singh, Moganavelli

doi:10.3390/pharmaceutics13060900

Cited by 44 publications

(36 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, polymers such as dendrimers have been popular due to their many cationic groups. They have been further utilized as suitable stabilizers of metallic NPs such as AuNPs [82,83]. Poly (lactic-co-glycolic acid), a polymer approved by the Food and Drug Administration (FDA), has shown good properties for use in drug delivery in combination with Au [84], while its PEGylated derivatives have been investigated in AD [85].…”

Section: Nanoparticles and Nanomedicinementioning

confidence: 99%

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

Jagaran

Singh

2021

IJMS

Self Cite

View full text Add to dashboard Cite

Neurodegenerative disorders involve the slow and gradual degeneration of axons and neurons in the central nervous system (CNS), resulting in abnormalities in cellular function and eventual cellular demise. Patients with these disorders succumb to the high medical costs and the disruption of their normal lives. Current therapeutics employed for treating these diseases are deemed palliative. Hence, a treatment strategy that targets the disease’s cause, not just the symptoms exhibited, is desired. The synergistic use of nanomedicine and gene therapy to effectively target the causative mutated gene/s in the CNS disease progression could provide the much-needed impetus in this battle against these diseases. This review focuses on Parkinson’s and Alzheimer’s diseases, the gene/s and proteins responsible for the damage and death of neurons, and the importance of nanomedicine as a potential treatment strategy. Multiple genes were identified in this regard, each presenting with various mutations. Hence, genome-wide sequencing is essential for specific treatment in patients. While a cure is yet to be achieved, genomic studies form the basis for creating a highly efficacious nanotherapeutic that can eradicate these dreaded diseases. Thus, nanomedicine can lead the way in helping millions of people worldwide to eventually lead a better life.

show abstract

Section: Nanoparticles and Nanomedicinementioning

confidence: 99%

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

Jagaran

Singh

2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Polyamidoamine (PAMAM) dendrimers are the most common class of dendrimers utilized to date to deliver nucleic acids [42][43][44][45]. Dendrimers possess an inner alkyl-diamine core and a peripheral shell of tertiary amine branches [46,47].…”

Section: Angiopep-2-decorated Nanoparticlesmentioning

confidence: 99%

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Habib

Singh

2022

Polymers

Self Cite

View full text Add to dashboard Cite

Nanotechnology has opened up a world of possibilities for the treatment of brain disorders. Nanosystems can be designed to encapsulate, carry, and deliver a variety of therapeutic agents, including drugs and nucleic acids. Nanoparticles may also be formulated to contain photosensitizers or, on their own, serve as photothermal conversion agents for phototherapy. Furthermore, nano-delivery agents can enhance the efficacy of contrast agents for improved brain imaging and diagnostics. However, effective nano-delivery to the brain is seriously hampered by the formidable blood–brain barrier (BBB). Advances in understanding natural transport routes across the BBB have led to receptor-mediated transcytosis being exploited as a possible means of nanoparticle uptake. In this regard, the oligopeptide Angiopep-2, which has high BBB transcytosis capacity, has been utilized as a targeting ligand. Various organic and inorganic nanostructures have been functionalized with Angiopep-2 to direct therapeutic and diagnostic agents to the brain. Not only have these shown great promise in the treatment and diagnosis of brain cancer but they have also been investigated for the treatment of brain injury, stroke, epilepsy, Parkinson’s disease, and Alzheimer’s disease. This review focuses on studies conducted from 2010 to 2021 with Angiopep-2-modified nanoparticles aimed at the treatment and diagnosis of brain disorders.

show abstract

“…To improve transfection efficacy, cationic materials such as PEI or polyamidoamine (PAMAM) dendrimers were employed to coat the surface of inorganic nanoparticles with mRNA. PEI-and PAMAM-dendrimer-coated NPs showed high transfection activities owing to their branched structures and multiple amine groups [72,73]. Another attractive material, SeNPs possess lower toxicity, higher bioavailability, biodegradability, and antioxidant activity.…”

Section: Efforts To Improve Delivery Efficiencymentioning

confidence: 99%

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

et al. 2022

View full text Add to dashboard Cite

RNA therapeutics, including messenger RNA (mRNA) and small interfering RNA (siRNA), are genetic materials that mediate the translation of genetic direction from genes to induce or inhibit specific protein production. Although the interest in RNA therapeutics is rising globally, the absence of an effective delivery system is an obstacle to the clinical application of RNA therapeutics. Additionally, immunogenicity, short duration of protein expression, unwanted enzymatic degradation, and insufficient cellular uptake could limit the therapeutic efficacy of RNA therapeutics. In this regard, novel platforms based on nanoparticles are crucial for delivering RNAs to the targeted site to increase efficiency without toxicity. In this review, the most recent status of nanoparticles as RNA delivery vectors, with a focus on polymeric nanoparticles, peptidederived nanoparticles, inorganic nanoparticles, and hybrid nanoparticles, is discussed. These nanoparticular platforms can be utilized for safe and effective RNA delivery to augment therapeutic effects. Ultimately, RNA therapeutics encapsulated in nanoparticle-based carriers will be used to treat many diseases and save lives.

show abstract

Dendrimer-Coated Gold Nanoparticles for Efficient Folate-Targeted mRNA Delivery In Vitro

Cited by 44 publications

References 58 publications

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

Contact Info

Product

Resources

About